Skip to main content

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
Français FR
Home Home

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process
Français FR

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
  • Home /
  • Listing 3 - Actual negotiations

Listing 3 - Actual negotiations

Search by drug, manufacturer, or indication

Displaying 191 - 200 of 1165

Camcevi (leuprolide mesylate)

Status:

Concluded with an LOI

Manufacturer:

Accord Healthcare Inc.

Indication:

For the treatment of adult patients with advanced prostate cancer

Last updated October 31, 2025

Nordimet (methotrexate)

Status:

Concluded without agreement

Manufacturer:

Nordic Pharma

Indication:

Multiple Indications

Last updated October 30, 2025

Opdivo SC (nivolumab)

Status:

Concluded with an LOI

Manufacturer:

Bristol Myers Squibb Canada Inc.

Indication:

Multiple Indications

Last updated October 29, 2025

Abilify Asimtufii (aripiprazole)

Status:

Concluded with an LOI

Manufacturer:

Otsuka Canada Pharmaceutical Inc.

Indication:

Schizophrenia

Last updated October 24, 2025

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

For the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumours express PD-L1 [Combined Positive Score (CPS) ? 1], as neoadjuvant treatment as monotherapy, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as monotherapy.

Last updated October 23, 2025

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

For the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT).

Last updated October 23, 2025

Ferinject (ferric carboxymaltose)

Status:

Concluded with an LOI

Manufacturer:

CSL Vifor

Indication:

Iron Deficiency Anemia

Last updated October 17, 2025

Ferinject (ferric carboxymaltose)

Status:

Concluded with an LOI

Manufacturer:

CSL Vifor

Indication:

Iron deficiency in adult patients with heart failure

Last updated October 17, 2025

Ayvakyt (avapritinib)

Status:

Concluded with an LOI

Manufacturer:

Medison Pharma Canada Inc.

Indication:

Advanced Systemic Mastocytosis

Last updated October 17, 2025

Oslya (denosumab)

Status:

Concluded with an LOI

Manufacturer:

Mantra Pharma

Indication:

Multiple Indications

Last updated October 14, 2025

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 18
  • Page 19
  • Current page 20
  • Page 21
  • Page 22
  • …
  • Next page Next ›
  • Last page Last »

Page updated: February 12, 2026

Our team is located across the country, on the ancestral and unceded territories of Canada’s Indigenous Peoples. We recognize their inherent and treaty rights, and we’re grateful to stand, live, and work on these lands.

pan-Canadian Pharmaceutical Association

General inquiries: Email us

Footer Navigation

  • Inside the pCPA
    • Who we are
    • What we do
    • Our vision and strategy
    • Governance
    • Members
  • Insights and updates
    • Our role
    • Drugs we negotiate
    • Performance dashboard
    • News
    • Glossary
  • Negotiations
    • Recent negotiation activity
    • Standard negotiations
    • Expedited pathways
    • Biosimilar drugs
    • Brand-name drugs
    • Generic Drugs

Footer secondary

  • Browse negotiations
  • Careers
  • Contact us
  • News

Copyright © 2026 pan-Canadian Pharmaceutical Alliance. All rights reserved.

Footer Utility

  • Privacy Policy
  • Terms of use